home / stock / crxtw / crxtw quote
Last: | $0.0136 |
---|---|
Change Percent: | -77.33% |
Open: | $0.019 |
Close: | $0.06 |
High: | $0.0211 |
Low: | $0.0112 |
Volume: | 435,910 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0136 | $0.019 | $0.06 | $0.0211 | $0.0112 | 435,910 | 08-30-2022 |
$0.0207 | $0.0225 | $0.06 | $0.0259 | $0.0186 | 292,886 | 08-29-2022 |
$0.0321 | $0.0332 | $0.06 | $0.0401 | $0.0281 | 121,875 | 08-26-2022 |
$0.0311 | $0.0309 | $0.06 | $0.0331 | $0.0309 | 24,191 | 08-25-2022 |
$0.03 | $0.02 | $0.06 | $0.03 | $0.02 | 94,487 | 08-24-2022 |
$0.0255 | $0.028 | $0.06 | $0.03 | $0.025 | 124,155 | 08-23-2022 |
$0.0305 | $0.038 | $0.06 | $0.0399 | $0.0289 | 287,008 | 08-22-2022 |
$0.0379 | $0.0556 | $0.06 | $0.0556 | $0.0299 | 311,836 | 08-19-2022 |
$0.065 | $0.0738 | $0.06 | $0.0738 | $0.06 | 29,828 | 08-18-2022 |
$0.0769 | $0.0598 | $0.06 | $0.0769 | $0.0465 | 59,078 | 08-17-2022 |
$0.0598 | $0.061 | $0.06 | $0.069 | $0.0553 | 4,699 | 08-16-2022 |
$0.0595 | $0.0597 | $0.06 | $0.08 | $0.0595 | 18,445 | 08-15-2022 |
$0.0597 | $0.055 | $0.06 | $0.06 | $0.05 | 91,345 | 08-12-2022 |
$0.0651 | $0.0698 | $0.06 | $0.079 | $0.0651 | 8,195 | 08-11-2022 |
$0.0652 | $0.065201 | $0.06 | $0.0724 | $0.0651 | 14,529 | 08-10-2022 |
$0.0666 | $0.0666 | $0.06 | $0.0666 | $0.0666 | 3,947 | 08-09-2022 |
$0.07 | $0.059 | $0.06 | $0.0701 | $0.059 | 6,414 | 08-08-2022 |
$0.0619 | $0.0568 | $0.06 | $0.07 | $0.052 | 36,558 | 08-05-2022 |
$0.051 | $0.0597 | $0.06 | $0.0597 | $0.051 | 20,448 | 08-04-2022 |
$0.055 | $0.0597 | $0.06 | $0.0597 | $0.055 | 22,730 | 08-03-2022 |
News, Short Squeeze, Breakout and More Instantly...
Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 Company Name:
CRXTW Stock Symbol:
NASDAQ Market:
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary ...
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcou...
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT)...